• Maximus, Inc. recently declared a quarterly cash dividend of US$0.33 per share, payable on June 1, 2026, to shareholders of record as of May 15, 2026, while also raising its full-year adjusted earnings per share outlook and narrowing its revenue forecast following a divestiture.
• The dividend increase, upgraded EPS guidance, and extensive share repurchases highlight management’s emphasis on returning capital to investors while signaling confidence in the company’s ability to generate cash.
• Next, we’ll examine how the higher EPS guidance and dividend increase may reshape Maximus’ investment narrative for long-term investors.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

Maximus Investment Narrative Recap

To own Maximus, you generally need to believe that governments will keep leaning on third parties for complex, technology-enabled program administration, and that Maximus can defend and expand its role in those contracts. The raised EPS outlook and steady dividend support that view, but they do not materially change the near term catalyst around new legislation-driven contract awards, nor do they remove the key risk that automation and tighter budgets could curb demand for traditional outsourcing.

Among the recent announcements, the upgraded full year adjusted EPS guidance to US$8.05–US$8.35 stands out alongside the stable US$0.33 dividend. Together, they sit against a backdrop of slower forecast revenue growth of about 3.3% per year, underscoring how efficiency and mix shift have become central to the thesis. For investors watching catalysts, this guidance update is a useful reference point when weighing upcoming Medicaid, SNAP, and other regulatory-driven contract opportunities.

Yet behind the higher EPS outlook, investors should still pay attention to the growing automation and AI risk that could eventually reduce governments’ reliance on Maximus’ labor intensive services...

Maximus' narrative projects $6.1 billion revenue and $486.5 million earnings by 2028. This requires 3.9% yearly revenue growth and about a $170 million earnings increase from $316.2 million today.

Uncover how Maximus' forecasts yield a $110.00 fair value, a 69% upside to its current price.

Exploring Other Perspectives

Before this dividend and guidance update, the most optimistic analysts were modeling revenue of about US$6.2 billion and earnings near US$513 million by 2028, which paints a far more upbeat picture than consensus. If you lean toward that view, the latest higher EPS guidance might look like early support for a faster earnings path, but it could also prompt a rethink if automation and AI adoption in government services prove more disruptive than expected.

Explore 2 other fair value estimates on Maximus - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Maximus research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Maximus research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Maximus' overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.